Colormap-Enhanced Vision Transformers for MRI-Based Multiclass (4-Class) Alzheimer's Disease Classification
This work addresses the challenge of subtle structural variations in brain MRI scans for Alzheimer's disease diagnosis, offering a tool to support clinical decision-making, though it appears incremental as it combines existing techniques (colormap transformations with Vision Transformers).
The paper tackles Alzheimer's disease classification from MRI scans by proposing PseudoColorViT-Alz, a colormap-enhanced Vision Transformer framework that amplifies anatomical texture and contrast cues, achieving state-of-the-art accuracy of 99.79% and AUC of 100% on the OASIS-1 dataset for four-class classification.
Magnetic Resonance Imaging (MRI) plays a pivotal role in the early diagnosis and monitoring of Alzheimer's disease (AD). However, the subtle structural variations in brain MRI scans often pose challenges for conventional deep learning models to extract discriminative features effectively. In this work, we propose PseudoColorViT-Alz, a colormap-enhanced Vision Transformer framework designed to leverage pseudo-color representations of MRI images for improved Alzheimer's disease classification. By combining colormap transformations with the global feature learning capabilities of Vision Transformers, our method amplifies anatomical texture and contrast cues that are otherwise subdued in standard grayscale MRI scans. We evaluate PseudoColorViT-Alz on the OASIS-1 dataset using a four-class classification setup (non-demented, moderate dementia, mild dementia, and very mild dementia). Our model achieves a state-of-the-art accuracy of 99.79% with an AUC of 100%, surpassing the performance of recent 2024--2025 methods, including CNN-based and Siamese-network approaches, which reported accuracies ranging from 96.1% to 99.68%. These results demonstrate that pseudo-color augmentation combined with Vision Transformers can significantly enhance MRI-based Alzheimer's disease classification. PseudoColorViT-Alz offers a robust and interpretable framework that outperforms current methods, providing a promising tool to support clinical decision-making and early detection of Alzheimer's disease.